Trial Questions Continuous Maintenance in Newly Diagnosed Myeloma

A phase III trial (ENDURANCE) found that continuous lenalidomide (Revlimid) maintenance therapy did not significantly improve overall survival in patients with standard-risk, newly diagnosed multiple myeloma. The results question the effectiveness of continuous maintenance in this patient group.